Cargando…
Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy
Histone deacetylase inhibitors (HDACi) have been approved and achieved success in hematologic malignancies. But its application in solid tumors still confronts big challenges and is hampered by low treatment efficacy. Nanotechnology has been widely applied in cancer therapy, and nanomedicine could i...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284110/ https://www.ncbi.nlm.nih.gov/pubmed/32582697 http://dx.doi.org/10.3389/fcell.2020.00400 |
_version_ | 1783544396103286784 |
---|---|
author | Tu, Bin Zhang, Meng Liu, Tuanbing Huang, Yongzhuo |
author_facet | Tu, Bin Zhang, Meng Liu, Tuanbing Huang, Yongzhuo |
author_sort | Tu, Bin |
collection | PubMed |
description | Histone deacetylase inhibitors (HDACi) have been approved and achieved success in hematologic malignancies. But its application in solid tumors still confronts big challenges and is hampered by low treatment efficacy. Nanotechnology has been widely applied in cancer therapy, and nanomedicine could improve drug stability, prolong the circulation half-life, and increase intratumoral drug accumulation. Therefore, nanomedicine is a promising strategy to enhance HDACi therapy efficacy. The review provides a summary of the advances of HDACi nanomedicines with a focus on the design principles of the targeting delivery systems for HDACi. |
format | Online Article Text |
id | pubmed-7284110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-72841102020-06-23 Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy Tu, Bin Zhang, Meng Liu, Tuanbing Huang, Yongzhuo Front Cell Dev Biol Cell and Developmental Biology Histone deacetylase inhibitors (HDACi) have been approved and achieved success in hematologic malignancies. But its application in solid tumors still confronts big challenges and is hampered by low treatment efficacy. Nanotechnology has been widely applied in cancer therapy, and nanomedicine could improve drug stability, prolong the circulation half-life, and increase intratumoral drug accumulation. Therefore, nanomedicine is a promising strategy to enhance HDACi therapy efficacy. The review provides a summary of the advances of HDACi nanomedicines with a focus on the design principles of the targeting delivery systems for HDACi. Frontiers Media S.A. 2020-06-03 /pmc/articles/PMC7284110/ /pubmed/32582697 http://dx.doi.org/10.3389/fcell.2020.00400 Text en Copyright © 2020 Tu, Zhang, Liu and Huang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Tu, Bin Zhang, Meng Liu, Tuanbing Huang, Yongzhuo Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy |
title | Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy |
title_full | Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy |
title_fullStr | Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy |
title_full_unstemmed | Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy |
title_short | Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy |
title_sort | nanotechnology-based histone deacetylase inhibitors for cancer therapy |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284110/ https://www.ncbi.nlm.nih.gov/pubmed/32582697 http://dx.doi.org/10.3389/fcell.2020.00400 |
work_keys_str_mv | AT tubin nanotechnologybasedhistonedeacetylaseinhibitorsforcancertherapy AT zhangmeng nanotechnologybasedhistonedeacetylaseinhibitorsforcancertherapy AT liutuanbing nanotechnologybasedhistonedeacetylaseinhibitorsforcancertherapy AT huangyongzhuo nanotechnologybasedhistonedeacetylaseinhibitorsforcancertherapy |